New hope for kidney cancer: drug combo after radiation shows promise in early trial
NCT ID NCT07223541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two immunotherapy drugs, cemiplimab and fianlimab, given after targeted radiation for kidney cancer that has spread to a few spots in the body. The goal is to see if adding fianlimab helps control the cancer longer than cemiplimab alone. About 72 adults with clear cell renal cell carcinoma and up to 5 metastatic lesions will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact